Clinical trials: Vascular Conditions
Intracerebral Hemorrhage
High-Dose Deferoxamine in Intracerebral Hemorrhage
The main purpose of this study is to determine whether treatment with deferoxamine mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for brain…
- Trial name
- HI-DEF (NCT01662895)
- Testing
- Deferoxamine, Normal saline
- Where
- 29 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Beth Israel Deaconess Medical Center
Peripheral Vascular Disease, Intermittent Claudication
Evaluation of Cilostazol in Combination With L-Carnitine
The purpose of this study is to see how safe and effective L carnitine taken with cilostazol is compared to placebo taken with cilostazol for people with intermittent claudication.
- Conditions
- Peripheral Vascular Disease, Intermittent Claudication, Peripheral Arterial Disease
- Trial name
- ECLECTIC (NCT00822172)
- Testing
- Levocarnitine tartrate, cilostazol
- Where
- 24 sites in United States
- Volunteers
- 164 people
- Sponsor
- Colorado Prevention Center
Relapsed or Refractory Multiple Myeloma
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
The investigators will perform a phase I/II trial of Revlimid daily for 21 days and Abraxane weekly for 3 weeks. Accrual will be on standard cohorts of 3 patients.
- Trial name
- rev/abraxane (NCT02075021)
- Testing
- Lenalidomide, nab-paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Oxidative Stress, Inflammation
Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution
This study aims to evaluate whether dietary supplementation with fish oil can protect against the cardiopulmonary alterations linked to air pollution
- Conditions
- Oxidative Stress, Inflammation, Blood Pressure, Vasoconstriction
- Trial name
- NCT03255187
- Testing
- Fish oil supplementation, Sunflower seed oil supplementation
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Fudan University
Myocardial Infarction
Management of Anger in Patients With Acute Myocardial Infarction (MAPAMI)
Stress, anger and depressed can operate as a trigger to an Acute Coronary Syndrome. It is often found in the literature that patients refer excessive anger, anxiety, sadness, pain or acute stress before the acute myocardial…
- Trial name
- MAPAMI (NCT02868216)
- Testing
- anger management training
- Volunteers
- 90 people
- Sponsor
- Instituto de Cardiologia do Rio Grande do Sul
Renal Insufficiency, Chronic, Hypertension
Supporting Self-Management of Healthy Behaviors in Diabetes, Kidney Disease, and Hypertension
The planned intervention, entitled, Supporting Self-Management of Health Behaviors to Optimize Health (SMART-HABITS for Health), aims to provide support for patients with chronic kidney disease (CKD), hypertension and diabetes by…
- Conditions
- Renal Insufficiency, Chronic, Hypertension, Diabetes
- Trial name
- NCT05565716
- Testing
- Support Person, Social Norms
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Pennsylvania
Acute Ischemic Stroke
Imaging Guided Patient Selection for Interventional Revascularization Therapy
The primary objective of this clinical evaluation is to determine the safety and effectiveness of the Penumbra System in a stroke cohort who presents within 8 hours from symptom and with a known core infarct volume at admission.
- Trial name
- START (NCT00963989)
- Testing
- Penumbra System
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Penumbra Inc.
Ischemia-Reperfusion Injury, Kidney Diseases
Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation
The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Reparixin is a novel, specific inhibitor of CXCL8.
- Trial name
- NCT00248040
- Testing
- Reparixin continuous infusion, reparixin intermittent infusion
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Dompé Farmaceutici S.p.A
Multiple Myeloma, AL Amyloidosis
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with…
- Conditions
- Multiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia
- Trial name
- NCT05028374
- Testing
- A single "booster" dose of the Moderna mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Myocardial Infarction
Mental Stress and Myocardial Ischemia After MI: Sex Differences, Mechanisms and Prognosis
The purpose of this study is to look at the link between emotional stress and heart disease in men and women. Taking part in this study involves one clinic visit, one week of at home monitoring, and follow up phone calls every 6…
- Trial name
- MIMS3 (NCT04123197)
- Testing
- Stress Challenge
- Where
- 3 sites in United States
- Volunteers
- 306 people
- Sponsor
- Emory University
Coronary Artery Disease, Angina, Unstable
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
This is a phase II multi-centre study in 140 patients undergoing elective PCI to obtain the information on dose-response of argatroban in pharmacodynamic markers and to assess the anticoagulation, safety and efficacy of…
- Trial name
- NCT00508924
- Testing
- Argatroban, Heparin
- Where
- 8 sites in Belgium, Germany
- Volunteers
- 140 people
- Sponsor
- Tanabe Pharma Corporation
Acute Coronary Syndrome
European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial
To show that the early administration of bivalirudin improves 30 day outcomes when compared to the current standard of care in participants with ST segment elevation acute coronary syndrome (STE-ACS), intended for a primary…
- Trial name
- EUROMAX (NCT01087723)
- Testing
- Bivalirudin, Heparin
- Where
- 145 sites in Austria, Czechia and 7 more
- Volunteers
- 2,198 people
- Sponsor
- The Medicines Company
Central Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
- Trial name
- RAVEN (NCT03810313)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 120 sites in United States, Australia and 18 more
- Volunteers
- 493 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Diseases, Hypertension
Cardiovascular Risk Screening and Risk Reduction in Women Vets
Cardiovascular (CV) disease is the number one cause of death in American women, and all adult women are potentially at risk for CV disease.
- Conditions
- Cardiovascular Diseases, Hypertension, Hyperlipidemias, Dyslipidemias
- Trial name
- NCT02991534
- Testing
- CV Toolkit Components
- Where
- 4 sites in United States
- Volunteers
- 6,009 people
- Sponsor
- VA Office of Research and Development
Cardiovascular Disease
Cardiovascular Inflammation Reduction Trial
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic…
- Trial name
- CIRT (NCT01594333)
- Testing
- Methotrexate
- Where
- 470 sites in United States, Canada and 1 more
- Volunteers
- 4,786 people
- Sponsor
- Brigham and Women's Hospital
Myocardial Ischemia
The Effects of Intravenous Heme Arginate on Heme Oxygenase-1 Expression (HO-1) and Oxidative Stress in the Human Heart
Ischemia reperfusion injury may be attenuated by HO-1 induction. Our previous data confirmed strong HO-1 induction in peripheral blood cells following heme arginate infusion in healthy humans.
- Trial name
- NCT02314780
- Testing
- Heme arginate 3mg/kg, Heme arginate 1mg/kg
- Where
- Austria
- Volunteers
- 31 people
- Sponsor
- Martin Andreas, M.D.
Critical Limb Ischemia
Percutaneous Deep Vein Arterialization Post-Market Study
The objective of this post-market study is to evaluate the safety and effectiveness of the LimFlow System in creating a below-the-knee arterio-venous fistula for venous arterialization in subjects with critical limb ischemia.
- Trial name
- PROMISE UK (NCT03807661)
- Testing
- Percutaneous deep vein arterialization, LimFlow System
- Where
- 6 sites in United Kingdom
- Volunteers
- 28 people
- Sponsor
- LimFlow SA
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT02037256
- Testing
- bortezomib, filgrastim, autologous hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Diabetes Mellitus, Type 2, Acute Myocardial Infarction
Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
The primary objective was to demonstrate a difference between two insulin strategies, one targeting postprandial (PP) hyperglycemia and the other targeting fasting and interprandial hyperglycemia, on time until the first combined…
- Trial name
- IONM (NCT00191282)
- Testing
- Insulin lispro, Human insulin isophane suspension (NPH), Insulin glargine
- Where
- 17 sites in Canada, Croatia and 15 more
- Volunteers
- 1,116 people
- Sponsor
- Eli Lilly and Company
Atrial Fibrillation, Thromboembolism
A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
This study is to assess the safety of a potential new drug DU-176b for the prevention of stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation (AF).
- Trial name
- NCT00504556
- Testing
- Edoxaban (DU-176b), warfarin
- Where
- 91 sites in United States, Belarus and 10 more
- Volunteers
- 1,146 people
- Sponsor
- Daiichi Sankyo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.